These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9535601)

  • 1. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study.
    Kuriyama M; Ueno K; Uno H; Kawada Y; Akimoto S; Noda M; Nasu Y; Tsushima T; Ohmori H; Sakai H; Saito Y; Meguro N; Usami M; Kotake T; Suzuki Y; Arai Y; Shimazaki J
    Int J Urol; 1998 Jan; 5(1):48-54. PubMed ID: 9535601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases.
    Kuriyama M; Abrahamsson PA; Imai K; Akimoto S; Deguchi N; Shichiri Y; Sugiyama Y; Niwa T; Inoue T
    Scand J Urol Nephrol; 2001 Feb; 35(1):5-10. PubMed ID: 11291689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein.
    Akino H; Suzuki Y; Oyama N; Kanamaru H; Okada K
    Int J Urol; 1999 Sep; 6(9):440-5. PubMed ID: 10510889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of prostate-specific antigen--alpha(1)-antichymotrypsin complex for diagnosis and staging of prostate cancer.
    Hara I; Miyake H; Hara S; Yamada Y; Takechi Y; Fujisawa M; Okada H; Arakawa S; Kamidono S
    Jpn J Clin Oncol; 2001 Oct; 31(10):506-9. PubMed ID: 11696621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
    Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
    Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease.
    España F; Martínez M; Sánchez-Cuenca J; Vera CD; Estellés A; Jiménez-Cruz JF
    Eur Urol; 1996; 30(4):512-8. PubMed ID: 8977078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
    Björk T; Bjartell A; Abrahamsson PA; Hulkko S; di Sant'Agnese A; Lilja H
    Urology; 1994 Apr; 43(4):427-34. PubMed ID: 7512295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
    Wan XS; Xu YA; Ware JH; Kennedy AR
    Prostate; 2003 Jul; 56(2):131-41. PubMed ID: 12746838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
    Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
    Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L.
    Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF
    Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
    Saika T; Tsushima T; Nasu Y; Kusaka N; Miyaji Y; Takamoto H; Takeda K; Uno S; Kumon H;
    Cancer; 2002 Mar; 94(6):1685-91. PubMed ID: 11920529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
    Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
    J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay].
    Chichibu K; Kuroe K; Hashimoto C; Goto S
    Rinsho Byori; 1995 Nov; 43(11):1153-8. PubMed ID: 8551680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
    Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
    Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.